Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... tender offer by its indirect wholly-owned subsidiary, Sapphire Subsidiary ... common stock of Solta Medical, Inc. (NASDAQ: ...
Breaking Medicine Technology:BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... , May 25 A record 235 new ... being developed by America,s pharmaceutical research and biotechnology companies, according to a ... , , ... adult population suffers from diabetes—a rate that has more than doubled since ...
... HELMOND, The Netherlands , May 25, 2010 Blue Medical ... life of,patients with cardiovascular disease, with the start of the PIONEER trial, in,which ... , , ... clinical program, is the trial that,enables for the first time the delivery of ...
Cached Medicine Technology:New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 2New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 3New Report Shows Record Number of Medicines Currently in Development to Treat Diabetes 4First Coronary Stent on Drug Eluting Balloon Implanted 2
(Date:4/15/2014)... RECIST Working Group published in the European Journal of ... categorization of tumor response or various aspects of progression could ... They found that modeling target lesion tumor growth did not ... of the other components of progression. The RECIST Working Group ...
(Date:4/14/2014)... been made in chemotherapy over the past decade, but ... continues to be a major challenge. , Nanotechnology ... the use of nanocarriers, or capsules, that can transport ... body. , The catch? These carriers are tiny, and ...
(Date:4/14/2014)... Henry Ford Hospital reached a medical milestone April 3, ... novel way to access the heart. , Henry Ford ... the unique procedure called transcaval valve replacement, which accesses ... Northern Michigan resident Viola Waller, 80, underwent Henry Ford,s ...
(Date:4/14/2014)... , , Penicillin, one of the scientific marvels of the ... it once won against bacterial infections. But scientists at ... new approach to restoring its combat effectiveness, even against ... the power of the penicillin family of drugs since ...
(Date:4/14/2014)... an active role in their radiation treatment decisions leaves ... may even relieve psychological distress around the experience, researchers ... University of Pennsylvania report in the journal ... undergoing radiation treatment, Neha Vapiwala, MD , an ...
Breaking Medicine News(10 mins):Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2Health News:Nano shake-up 2Health News:Henry Ford Hospital hits new heart valve surgery milestone 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... Each year the American Institute of Biological Sciences ... contributions to the biological sciences. The AIBS ... to announce the following award winners for 2009: ... PhD, University of Washington, Outstanding Service Award: Robert ...
... Calif., May 15 Cord Blood America, Inc. (OTC ... preservation company ( http://www.cordblood-america.com ) ... cells to families nationwide and internationally, said today that ... In audio interview with analyst Francis Gaskins, explains the ...
... 15 The YWCA USA presented its prestigious 2009 ... Justice and YWCA Niagara for Women,s Economic Advancement at ... Washington, D.C. They were selected among six exemplary initiatives ... , , YWCA Central Massachusetts was honored ...
... Cigna Medical Group has announced the opening of its ... the total number of CareToday clinics to six.CareToday Anthem ... Daisy Mountain Drive and Gavilan Peak Parkway, 39510 North ... practitioners and physician assistants, the clinics offer after hours ...
... to be the fourth fatality in the U.S. , , FRIDAY, ... the swine flu outbreak has yet to run its current ... schools were closed Thursday after dozens of flu-like infections surfaced ... ventilator, according to published reports. , Meanwhile, a woman in ...
... with trastuzumab (Herceptin) to treat women who have metastatic ... their treatment options. , At the 45th Annual Meeting ... (ASCO), researchers from the Mayo Clinic campus ... vinorelbine, and trastuzumab offers a treatment option that is ...
Cached Medicine News:Health News:AIBS honors outstanding contributions to biology 2Health News:AIBS honors outstanding contributions to biology 3Health News:AIBS honors outstanding contributions to biology 4Health News:AIBS honors outstanding contributions to biology 5Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 2Health News:Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory 3Health News:YWCA USA 2009 Hallmark Initiative Awards Presented to YWCA Central Massachusetts and YWCA Niagara 2Health News:Cigna Medical Group Announces Grand Opening of CareToday Clinic in Anthem, Ariz. 2Health News:Swine Flu Closes Three Schools in NYC 2Health News:Swine Flu Closes Three Schools in NYC 3Health News:Swine Flu Closes Three Schools in NYC 4Health News:Swine Flu Closes Three Schools in NYC 5Health News:Swine Flu Closes Three Schools in NYC 6Health News:Swine Flu Closes Three Schools in NYC 7Health News:Swine Flu Closes Three Schools in NYC 8Health News:Swine Flu Closes Three Schools in NYC 9Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 2Health News:Triple drug combination is promising option to treat metastatic HER2+ breast cancer 3
Shafts angled 45 degrees, 10 mm from tip to bend. 1 x 2 teeth. Serrated handle with polished finish. Most popular size or model....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Serrated tips, straight platforms....
Curved shafts with fine pointed tips. Smooth handle with dull finish....
Medicine Products: